TRACON Pharmaceuticals develops targeted therapies for people with cancer and related diseases. The current pipeline has three clinical-stage product candidates, each addressing a unique cellular process that is expected to complement currently available therapies.

TRACON aims to develop effective and well-tolerated treatments for underserved populations with the ultimate goal of enhancing survival and quality of life while maximizing shareholder value.